Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer [Yahoo! Finance]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Yahoo! Finance
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced the appointment of McDavid Stilwell as Chief Financial Officer. “We're excited to welcome McDavid to the Atsena team as we look to build upon our strong clinical progress and the momentum from our oversubscribed Series C financing,” said Patrick Ritschel, MBA, Chief Executive Officer of Atsena Therapeutics. “His strategic and operational expertise will be invaluable as we continue to advance our pipeline of therapies with first- and best-in-class potential for the treatment of inherited retinal diseases, including our ongoing Phase I/II/III LIGHTHOUSE trial of ATSN-201 in X-linked retinoschisis.” “I'm thrilled to join Atsena during this exciting time in the company's evolution, as we move toward initiation of the pivotal portion of the LIGHTHOUSE trial in the first q
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseGlobeNewswire
- How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyGlobeNewswire
SGMO
Earnings
- 11/6/25 - Miss
SGMO
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- SGMO's page on the SEC website